ライフサイエンスコーパス: diuretics

1 e management, typically addressed using loop diuretics.

2 d overload despite significant doses of loop diuretics.

3 the target of the clinically important loop diuretics.

4 ngiotensin-converting enzyme inhibitors, and diuretics.

5 es of antihypertensive medications, thiazide diuretics.

6 randomized to ultrafiltration or intravenous diuretics.

7 miloride 40 mg was as effective as the other diuretics.

8 randomized to ultrafiltration or intravenous diuretics.

9 ir actions on glycemic control or as osmotic diuretics.

10 oportion of instructions given for fluid and diuretics.

11 of SPIRO and a potential target for thiazide diuretics.

12 cluding vasopressors, intravenous fluids, or diuretics.

13 o in addition to standard therapy, including diuretics.

14 bitors plus diuretics and beta-blockers plus diuretics.

15 diabetes development than beta-blockers and diuretics.

16 risk of CVD mortality vs beta-blockers plus diuretics.

17 es to the cytoprotection afforded by osmotic diuretics.

18 U-50488H and bremazocine are analgesics and diuretics.

19 erting enzyme inhibitors, beta blockers, and diuretics.

20 mically guided therapy with vasodilators and diuretics.

21 patients who were relatively unresponsive to diuretics.

22 typically limited to a brief course of oral diuretics.

23 ion 21+/-1%) treated with ACE inhibitors and diuretics.

24 el approach to potentiate the action of loop diuretics.

25 c shock includes inotropes, vasopressors and diuretics.

26 thier patients are simply more responsive to diuretics.

27 aemia may lead to the creation of uricosuric diuretics.

28 imilar after the exclusion of individuals on diuretics.

29 es of GS with a blunted response to thiazide diuretics.

30 blockers, angiotensin receptor blockers, and diuretics.

31 was confirmed by the natriuretic response to diuretics.

32 estinal bleeding, and patients that required diuretics.

33 , 0.80-1.08), CCBs (1.27%; 0.96, 0.82-1.11), diuretics (1.30%; 0.98, 0.84-1.13), other controls (1.43

34 , 0.88-1.07), CCBs (2.11%; 1.05, 0.96-1.13), diuretics (2.02%; 1.00, 0.90-1.11), or other controls (1

35 diovascular medications (24.5%), followed by diuretics (22.1%), nonopioid analgesics (15.4%), hypogly

36 therapy (23.0% vs. 4.9% and 9.2%, p mu .01), diuretics (4.2% vs. 2.6% and 0.8%, p mu .001), or vasopr

37 0%) of beta-blockers, 10 of 11 RCTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers

38 At randomization, patients were receiving diuretics (95.9%), beta-blockers (82.5%), angiotensin-co

39 w ascites and peripheral edema, treated with diuretics, a low-salt diet, and fluid restriction.

40 he compounds currently in clinical trials as diuretics, a series of 1,4-substituted 8-cyclohexyl and

41 for a particular drug (PPIs, NSAIDs, SSRIs, diuretics, ACE inhibitors) in the 6 months prior to the

42 monly used antihypertensive agents including diuretics, ACE inhibitors, and ARBs.

43 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blocke

44 el antihypertensive therapy (mostly thiazide diuretics) added as needed to control blood pressure.

45 ohibit causal inference, it is unlikely that diuretics afford any material benefit in this clinical s

46 EI and ACEI+BB cohorts compared to that with diuretics alone were $444 and $33, respectively.

47 ors may be more appropriate than intravenous diuretics alone.

48 sive treatment (calcium-channel antagonists, diuretics, alpha-blockers, beta-blockers, and centrally

49 AHF therapies, such as diuretics, alter chloride homeostasis.

50 diuretic doses, and delays in the timing of diuretics among patients with acute decompensated heart

51 .35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors u

52 nction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors.

53 Beneficiaries initiating diuretics and beneficiaries initiating digoxin were more

54 n separate classes, with lowest adherence to diuretics and beta-blockers and highest adherence to ang

55 fficacy of antihypertensive drugs newer than diuretics and beta-blockers has not been established.

56 revious research has suggested that thiazide diuretics and beta-blockers may promote the development

57 Risks were similar for ACE inhibitors plus diuretics and beta-blockers plus diuretics.

58 nsin-converting enzyme inhibitors or between diuretics and beta-blockers.

59 d LVSD therapies (neurohormonal antagonists, diuretics and cardiac resynchronization in appropriate c

60 ation of incontinence, medications including diuretics and estrogen, obstetric history, physical exam

61 ,864 subjects; of these, 5,320 received loop diuretics and had dose data recorded.

62 es most strongly support the use of thiazide diuretics and long-acting calcium channel blockers as fi

63 or antagonist, enhances the response to loop diuretics and may have a renal protective effect.

64 ss by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxid

65 Diuretics and osmotic agents are controversial and poorl

66 sms and sites of action of loop and thiazide diuretics and the similarity of their chronic effects to

67 nd may be responsible for both resistance to diuretics and to endogenous natriuretic peptides.

68 summarizes available data on the use of both diuretics and UF in ADHF patients and identifies challen

69 in 11 patients we withdrew beta-blockers and diuretics and used phenylephrine and albumin infusion to

70 Despite inpatient diuretics and vasodilators targeting decongestion, persi

71 lcohol consumption, hypertension, and use of diuretics and was inversely associated with physical act

72 hibitors, angiotensin-receptor blockers, and diuretics and/or beta blockers in the prevention of hear

73 uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated w

74 mic beta blockers, calcium channel blockers, diuretics, and angiotensin receptor antagonists), smokin

75 et agents, warfarin, statins, beta-blockers, diuretics, and antiarrhythmic drugs.

76 h with the use of ARBs, ACEi, beta blockers, diuretics, and CCBs.

77 th angiotensin-converting enzyme inhibitors, diuretics, and digitalis.

78 that was successfully treated with steroids, diuretics, and dose interruptions.

79 f administration of antihypertensive agents, diuretics, and lipid lowering agents were also studied.

80 selection and doses of thiazide and similar diuretics, and the association of antihypertensive drug

81 II phenotypes, their sensitivity to thiazide diuretics, and the observation that they constitute a "m

82 either medical therapy (sodium restriction, diuretics, and total paracentesis) (n = 57) or medical t

83 A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patien

84 uric, nonsteroidal anti-inflammatories, loop diuretics, angiotensin II receptor antagonists, and beta

85 Thiazide diuretics, angiotensin II receptor blockers, and ACE inh

86 y used antihypertensive medications included diuretics, angiotensin-converting enzyme inhibitors (ACE

87 At 1 year, use of added open-label atenolol, diuretics, angiotensin-converting enzyme inhibitors, and

88 Hypersensitivity to thiazide and loop diuretics, angiotensin-converting enzyme inhibitors, and

89 Routine therapy included use of digoxin, diuretics, angiotensin-converting enzyme inhibitors, and

90 lure often progresses despite treatment with diuretics, angiotensin-converting enzyme inhibitors, bet

91 io to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, bet

92 , it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps

93 placebo, but they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhi

94 erapeutically important compounds, including diuretics, anticonvulsants and antidepressants, many of

95 commonly prescribed drugs (e.g. penicillins, diuretics, antivirals, methotrexate, and non-steroidal a

96 Thiazide diuretics are among the most commonly prescribed antihyp

97 Thiazide diuretics are among the most widely used treatments for

98 Loop diuretics are an essential component of therapy for pati

99 Thiazide-type diuretics are associated with an increased incidence of

100 Loop diuretics are commonly used to control congestive sympto

101 Diuretics are commonly used to treat hypertension and ex

102 l hypertension remains unknown, but thiazide diuretics are frequently recommended as first-line treat

103 Thiazide diuretics are frequently used in these patients for trea

104 Diuretics are secreted by the recently characterized org

105 r conclusion of this trial was that thiazide diuretics are superior in preventing 1 or more major for

106 The initial ALLHAT conclusion, that thiazide diuretics are superior to angiotensin-converting enzyme

107 Diuretics are superior to calcium channel blockers and,

108 Intravenous loop diuretics are the mainstay of therapy for patients with

109 Low-dose diuretics are the most effective first-line treatment fo

110 Diuretics are used in volume-expanded patients.

111 Osmotic diuretics are used successfully to alleviate acute tubul

112 Diuretics are used to decongest patients; however, morta

113 Thiazide diuretics are used to treat hypertension; however, compe

114 Thiazide diuretics are used worldwide as a first-choice drug for

115 ntly better than thiazides and thiazide-like diuretics as a first-line therapy for any outcome.

116 dence, and future trials should use low-dose diuretics as the standard for clinically useful comparis

117 s were found between groups for use of other diuretics, aspirin, antidepressants, antiepileptics, ant

118 Evaluation of Survival Trial) receiving loop diuretics at baseline were analyzed (N = 2,456).

119 : (1) observational: patients receiving loop diuretics at the Yale Transitional Care Center (N=162) a

120 ith HF (n=128) receiving treatment with loop diuretics at the Yale Transitional Care Center.

121 ALLHAT conclusion that thiazide and similar diuretics (at evidence-based doses) are the preferred fi

122 ontrast media, antiinflamatory, cytostatics, diuretics, beta blockers, anesthetics, analgesics, antie

123 n-converting enzyme inhibitors, digoxin, and diuretics, beta-blockers have strengthened the armamenta

124 total energy intake, body mass index, use of diuretics, beta-blockers, allopurinol, and uricosuric ag

125 Overall, the use of thiazide diuretics, beta-blockers, angiotensin-converting enzyme

126 Compared with patients assigned diuretics, beta-blockers, angiotensin-converting-enzyme

127 ficant differences in the responses to these diuretics between the patient groups in any of the urina

128 iabetes, hypertension medications, including diuretics, blood lead levels, and hyperlipidemia, the od

129 VASP as a potential determinant of thiazide diuretics BP response.

130 cs) to identify novel biomarkers of thiazide diuretics BP response.

131 ce NKCC2 is the molecular target of the loop diuretics bumetanide and furosemide, we asked about thei

132 lkalosis impairs the natriuretic response to diuretics, but the underlying mechanisms are unclear.

133 potassium after the initiation of digoxin or diuretics by Medicare beneficiaries.

134 I receptor blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metformin.

135 Binding of loop diuretics can curtail their action in the loop of Henle.

136 c therapy using any of several thiazide-type diuretics can more than double daily urine sodium excret

137 onger median time to the second dose of loop diuretics compared with long call patients (17.9 hours v

138 Conversely, there was lower adherence to diuretics compared with the other drug classes.

139 tense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet

140 The numbers of patients receiving digoxin or diuretics decreased at the most recent follow-up compare

141 ermine whether therapy with vasodilators and diuretics, designed to normalize loading conditions in d

142 Rodents chronically administered loop diuretics develop DR due to compensatory distal tubular

143 Diuretics, developed more than four decades ago, are use

144 angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect on natural history end

145 nce of comorbidities, and were more often on diuretics, digoxin, and angiotensin converting enzyme in

146 converting enzyme inhibitors, beta-blockers, diuretics, digoxin, and spironolactone in improving outc

147 herapy for congestive heart failure, such as diuretics, digoxin, angiotensin-converting enzyme inhibi

148 rently recommended for use in adults include diuretics, digoxin, angiotensin-converting enzyme inhibi

149 e formation of mineralized nodules, but loop diuretics do not.

150 uretic resistance, ultrafiltration before IV diuretics effectively and safely decreases length of sta

151 whether they took diet pills, laxatives, or diuretics, engaged in binge eating, induced vomiting, or

152 ckers-was significantly better than low-dose diuretics for any outcome.

153 otassium channel, ROMK, will represent novel diuretics for the treatment of hypertension.

154 ounder of epidemiology studies is the use of diuretics for treating hypertension.

155 When combined with diuretics, fully additive BP reduction is seen.

156 this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, wh

157 d in the ultrafiltration group and 11 in the diuretics group.

158 Recent animal studies suggest that certain diuretics have anticonvulsant activity.

159 decompensated heart failure (ADHF), and loop diuretics have historically been the cornerstone of trea

160 Thiazide diuretics have proven themselves effective again in the

161 that men using NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically relevant

162 of these risk factors, such as the effect of diuretics, have not been identified before in this group

163 es associated with the use of high-dose loop diuretics (HDLD).

164 .57; 95% confidence interval, 1.38 to 1.79), diuretics (HR, 1.95; 95% confidence interval, 1.73 to 2.

165 On univariable analysis, only diuretics, hsCRP, GZ, and core scar were associated with

166 ely with standard medical therapy, including diuretics, if they develop symptoms suggestive of heart

167 Diuretics improve symptoms but should be used in additio

168 an in addition to standard therapy including diuretics improved many, though not all, heart failure s

169 7 +/- 3.5 h of hospitalization and before IV diuretics in 20 heart failure patients with volume overl

170 ded transient dasatinib interruption in 83%, diuretics in 71%, pulse steroids in 27%, and thoracentes

171 idone (25 mg), amiloride (5 mg), and the two diuretics in combination, with a week off drug separatin

172 linded clinical trial, the widespread use of diuretics in critically ill patients with acute renal fa

173 The use of diuretics in critically ill patients with acute renal fa

174 The demonstrated efficacy of loop diuretics in managing congestion is balanced by the reco

175 assium-sparing and renal-function-protective diuretics in new studies.

176 our study demonstrate increased use of loop diuretics in patients with BP before the development of

177 e if ultrafiltration before intravenous (IV) diuretics in patients with decompensated heart failure a

178 tration may be an alternative to intravenous diuretics in patients with decompensated HF and volume o

179 luating the combination of loop and thiazide diuretics in patients with heart failure in order to des

180 Response to loop diuretics in patients with nephrotic syndrome (NS) is su

181 llowed by CCB and placebo, beta blockers and diuretics in rank order.

182 late osmotic stability are disrupted by loop diuretics in rats.

183 The efficacy of diuretics in the management of rosiglitazone (RSG)-induc

184 are not understood, including the action of diuretics in the treatment of ascites and the ability of

185 alysis of NCC protein demonstrated that loop diuretics increased NCC protein abundance by nearly 100%

186 ous antiarrhythmic drug use, previous use of diuretics, increased left atrial diameter, increased lef

187 and NF-kappaB activation produced by osmotic diuretics, indicating a role of adenosine metabolites in

188 al diuretic, or any intravenous therapy with diuretics, inotropes, or other vasoactive agents.

189 Chronic infusion of loop diuretics into animals induces structural and functional

190 ons of the current therapeutic regimens with diuretics, intravenous vasodilators (ie, nitroglycerin,

191 el mechanisms of nephroprotection by osmotic diuretics, involving both activation and induction of th

192 Potassium depletion by thiazide diuretics is associated with a rise in blood glucose.

193 ncluded that urinary protein binding of loop diuretics is not a major mechanism for the diuretic resi

194 hen administration of moderate doses of loop diuretics is not sufficient, patients can be treated wit

195 weight loss needs clarification, the role of diuretics is uncertain, and which surgical intervention

196 oconcentration received higher doses of loop diuretics, lost more weight/fluid, and had greater reduc

197 that inexpensive and well-tolerated thiazide diuretics may be especially effective in preventing the

198 in cells expressing NCC, indicating thiazide diuretics may be particularly effective for lowering BP

199 Thus, despite concerns that some diuretics may cause harm by neurohormonal activation, th

200 ministration of mixtures of albumin and loop diuretics may enhance responses.

201 vious concerns about the safety of high-dose diuretics may not be valid.

202 beta-receptor blockers, digoxin and thiazide diuretics may worsen sexual dysfunction owing to medicat

203 = 437), calcium-channel blockers (n = 223), diuretics (n = 226), and combinations (n = 1,442), beta-

204 Patients treated with diuretics (n=4) displayed higher abundance of full-lengt

205 in a control cohort without HF not receiving diuretics (n=52; 16.6%+/-9.2%; P=0.82).

206 lity in all subgroups except among men using diuretics (n=79) and men with 1 or more cardiovascular r

207 Thiazide diuretics, niacin, and beta-adrenergic blockers impair g

208 rs, beta-blockers, calcium channel blockers, diuretics, nitrates, statins, insulin, biguanides, sulfo

209 ecessive nephrolithiasis, but the effects of diuretics on calcium excretion and other stone risk fact

210 Patients treated with diuretics on or before the day of consultation were olde

211 Patients were categorized by the use of diuretics on the day of nephrology consultation and, in

212 nd ACEI+BB strictly dominated treatment with diuretics only (cost-saving).

213 There were no additional diuretics or changes in vasoactive agents during the stu

214 rate (eGFR) less than 50 mL/min, and taking diuretics or cyclosporine were associated with hyperuric

215 In Medicare beneficiaries initiating diuretics or digoxin, this study examined disparities in

216 bate cardiovascular problems from overuse of diuretics or inotropes because of the unusual loading co

217 , are usually treated with potassium-sparing diuretics or nonsteroidal anti-inflammatory drugs and or

218 ment modality and be prepared to discontinue diuretics or not proceed with TIPS placement should comp

219 encephalopathy, ascites requiring sustained diuretics or paracentesis, or coagulopathy unresponsive

220 ion of participants who were taking thiazide diuretics or those with diabetes.

221 te MI was present among nonusers of alcohol, diuretics, or aspirin and among those who did not have m

222 ersons who live in soft water areas, who use diuretics, or who are predisposed to magnesium loss or e

223 Loop diuretics other than furosemide were converted to furose

224 ic patients were more likely to be receiving diuretics (p < 0.0001) and have a lower mean corpuscular

225 t loss (p < 0.001), later transition to oral diuretics (p = 0.03), and shorter length of stay (p < 0.

226 with truly resistant hypertension, thiazide diuretics, particularly chlorthalidone, should be consid

227 when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of deve

228 correcting for relevant variables (including diuretics, pH, potassium levels and renal sodium excreti

229 events of coronary heart disease or stroke, diuretics plus ACE inhibitors or calcium channel blocker

230 calcium channel blockers did not differ from diuretics plus beta-blockers.

231 glycerides at baseline, high blood pressure, diuretics, pre-enrollment weight change, dieting, total

232 t to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a PSD may result in p

233 it from the use of chronic diuretic therapy, diuretics rapidly improve symptoms associated with volum

234 Diuretics reduce the rate of action potential fall in th

235 increase the volume of distribution of loop diuretics, reduce their tubular secretion, and enhance t

236 eater weight and fluid loss than intravenous diuretics, reduces 90-day resource utilization for HF, a

237 0.7 [95% confidence interval, 0.57-0.82] for diuretics; relative risk, 0.8 [95% confidence interval,

238 inition that excluded the intensification of diuretics resulted in a lower event rate but a stronger

239 eta-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, stat

240 pressin receptor antagonists, urea, and loop diuretics serve this purpose, but received different rec

241 Diuretics should be added in a stepwise fashion while ma

242 ifications to prevent CVD; (4) Thiazide-type diuretics should be used in drug treatment for most pati

243 Vasodilators and diuretics should generally be avoided.

244 tors' original conclusion that thiazide-type diuretics should remain the preferred first-step drug cl

245 The combination of statins and thiazide diuretics showed the greatest reduction in PSA levels: 3

246 The diuretics spironolactone and trichlormethiazide, but not

247 unds (mixture of anabolics, beta-2 agonists, diuretics, stimulants, narcotics, and beta-blockers) spi

248 the K-Cl cotransporter is dominated by loop diuretics such as furosemide and bumetanide, molecules u

249 All three loop diuretics suppressed sound-triggered seizures in post-is

250 n developing new classes of antihypertensive diuretics targeting ROMK.

251 was confirmed by the natriuretic response to diuretics targeting the thick ascending limb, the distal

252 Thiazide diuretics (TD) are commonly prescribed anti-hypertensive

253 In contrast to diuretics, the vasopressin antagonist tolvaptan may incr

254 ts otherwise resistant to high doses of loop diuretics, this strategy has not been subjected to large

255 nitroglycerin, or nesiritide in addition to diuretics to achieve hemodynamic and symptomatic improve

256 courage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypertension.

257 uggest that administration of high-dose loop diuretics to patients with HF yields meaningful increase

258 in converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment

259 Thiazide diuretics treat the disease, fostering the view that hyp

260 UT-B inhibitors represent a new class of diuretics, "urearetics," which are predicted to increase

261 od pressure less than 140/90 mm Hg; thiazide diuretics used in multidrug hypertensive regimen; athero

262 ass regimen of calcium channel blockers plus diuretics was associated with a higher risk of CVD morta

263 Monotherapy with calcium channel blockers vs diuretics was associated with greater risk of CVD death

264 Only the intake of diuretics was associated with substantially increased NT

265 Monotherapy with diuretics was equal or superior to other monotherapy in

266 reduction in office SBP produced by the two diuretics was identical, further strengthening the case

267 enal function (p = 0.01), whereas total dose diuretics was lower in patients with hemoconcentration (

268 ding intravenous treatment with inotropes or diuretics was the most common adverse event (in 20 [2%]

269 or other antihypertensive therapy (excluding diuretics) was administered at year 1.

270 or other antihypertensive therapy (excluding diuretics) was administered at year 1.

271 n, adiposity, weight gain, hypertension, and diuretics were all found to be independent risk factors

272 Compared with beta-blockers, low-dose diuretics were associated with a reduced risk of cardiov

273 Thiazide and loop diuretics were associated with higher risk of incident g

274 Thiazide and loop diuretics were associated with increased gout risk, an a

275 Compared with CCBs, low-dose diuretics were associated with reduced risks of cardiova

276 Compared with alpha-blockers, low-dose diuretics were associated with reduced risks of CHF (RR,

277 Compared with ACE inhibitors, low-dose diuretics were associated with reduced risks of CHF (RR,

278 itted to the ED and who received intravenous diuretics were included.

279 nd scheduled treatment with intravenous loop diuretics were included.

280 Beneficiaries initiating diuretics were less likely to have testing if they were

281 s with hypertension who were taking thiazide diuretics were not at greater risk for the subsequent de

282 , calcium channel blockers were inferior and diuretics were superior to other drug classes.

283 For all outcomes, low-dose diuretics were superior to placebo: coronary heart disea

284 Diuretics were used in 326 patients (59%) at the time of

285 Loop or thiazide diuretics were used in all 14 patients, and angiotensin-

286 Loop diuretics were used significantly more frequently by the

287 of the kidney and is the target of thiazide diuretics, which are commonly prescribed to treat hypert

288 Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporter in the

289 rs may complement the action of conventional diuretics, which target sodium transport.

290 ept for NSAIDs, ACE inhibitors, and thiazide diuretics, which were more prevalent in black patients.

291 between the two groups with the exception of diuretics, which were used more often in the DWGF group.

292 re likely to be treated with higher doses of diuretics, while higher filling pressures, N-terminal pr

293 Although diuretics will rightfully remain a cornerstone in antihy

294 Beneficiaries initiating diuretics with laboratory values were more likely to hav

295 bitors are first in their class salt-sparing diuretics with potential clinical indications in volume-

296 lockers, calcium-channel blockers [CCBs], or diuretics) with follow-up of at least 1 year.

297 n reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs were wide

298 r more effective fluid removal compared with diuretics, with improved quality of life and reduced reh

299 ive management includes salt restriction and diuretics, with thoracentesis and transjugular intrahepa

300 study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), minera